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Abstract Amino acid incorporation into proteins in vivo is
controlled most stringently by the aminoacyl-tRNA synthetases.
Here we report the incorporation of several new methionine
analogues into protein by increasing the rate of their activation
by the methionyl-tRNA synthetase (MetRS) of Escherichia coli.
cis-Crotylglycine (4), 2-aminoheptanoic acid (7), norvaline (8),
2-butynylglycine (11), and allylglycine (12) will each support
protein synthesis in methionine-depleted cultures of E. coli
when MetRS is overexpressed and the medium is supplemented
with the analogue at millimolar concentrations. These investiga-
tions suggest important opportunities for protein engineering, as
expansion of the translational apparatus toward other amino acid
analogues by similar strategies should also be possible. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The utilization of non-natural amino acids in the synthesis
of novel proteins has attracted increasing scienti¢c and tech-
nological interest. Strategies to incorporate non-natural amino
acids into proteins in vivo have relied on the ability of the
translational apparatus to accept a limited number of amino
acid analogues with structures similar to those of the protein-
ogenic amino acids. Although an essentially unlimited number
of non-natural amino acids can be incorporated into proteins
via chemical methods such as solid-phase peptide synthesis
and in vitro translation protocols [1,2], the incorporation of
non-natural amino acids into proteins in vivo o¡ers compel-
ling advantages over these alternative methods. In addition to
its synthetic simplicity and relatively high yields, the method
a¡ords multisite incorporation of non-natural amino acids,
which has important consequences for protein behavior.
The ¢delity of amino acid incorporation into proteins in
vivo is controlled most stringently by the aminoacyl-tRNA
synthetases (aaRS); the additional requirements of transport
into the cell and recognition by the elongation factors and the
ribosome [2,3] are generally more permissive than formation
of aminoacyl-tRNA. For this reason, e¡orts to diversify the
chemical composition of proteins by in vivo methods have
increasingly focused on manipulation of the aaRS. Indeed,
altering the aaRS activity of a bacterial host, by overexpres-
sion of wild-type [4], mutant [5], or heterologous synthetases
[6,7], has expanded the repertoire of amino acids that can be
used in protein biosynthesis.
Our continued interest in expanding the set of methionine
analogues that can be utilized by the translational apparatus
is motivated in part by the important role of methionine-rich
interfaces in controlling protein^protein interactions [8,9] ; re-
placement of methionine by chemically unique analogues may
permit control or covalent trapping of these events. The study
of methionine analogues may be uniquely fruitful in investi-
gations of this kind, as the permissiveness of the Escherichia
coli methionyl-tRNA synthetase (MetRS) has been demon-
strated in previous reports of the translational activity of a
variety of methionine analogues of varying chemical function-
ality and side chain length [10^13]. The critical role of MetRS
in controlling the incorporation of methionine analogues into
protein has been con¢rmed in studies in which the rates of
activation of 2^9 in vitro have been correlated with the ca-
pacity of each of the analogues to support protein synthesis in
vivo [4,14,15]. Here we present investigations of the activation
and translational activity of methionine analogues 2^13 under
a modi¢ed set of experimental conditions, and demonstrate
that the translational apparatus can accept a larger set of
methionine analogues than previously reported.
2. Materials and methods
2.1. Analogue synthesis
Each of the analogues 2^7 and 11 was prepared as previously de-
scribed [14,16]. Analogues 8, 9, 12, and 13 are available commercially
(Sigma-Aldrich, St. Louis, MO, USA), and analogue 10 was a gift
from Helen Blackwell (California Institute of Technology, Pasadena,
CA, USA). Analogues 2^7 and 10^13 were used as the racemates in
both in vivo and in vitro assays, and all concentrations given are for
the L-isomers of the analogues.
2.2. Bacterial expression hosts
The E. coli methionine auxotroph CAG18491 (V3, rph-1, met-
E3079: :Tn10), kindly provided by the Yale E. coli Genetic Stock
Center, was transformed with plasmids pREP4 and pQE15 (Qiagen),
to obtain the expression host CAG18491/pQE15/pREP4. The plasmid
pQE15 encodes the protein murine dihydrofolate reductase (mDHFR)
under the control of a bacteriophage T5 promoter. The expression
plasmid also encodes an N-terminal hexahistidine sequence that per-
mits puri¢cation of the target protein by immobilized metal chelate
a⁄nity chromatography. Furthermore, mDHFR contains eight me-
thionine residues that can be replaced by methionine analogues, and
its expression is easily monitored by sodium dodecyl sulfate^polyac-
rylamide gel electrophoresis (SDS^PAGE) and visualized by Coomas-
sie blue staining.
A modi¢ed bacterial expression host, CAG18491/pQE15-MRS/
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pREP4, was prepared by transforming CAG18491 with plasmids
pREP4 and pQE15-MRS. The plasmid pQE15-MRS encodes
mDHFR, like pQE15, but also encodes the truncated form of MetRS
[17] under control of the E. coli promoter metGp1 (GenBank accession
number X55791). Cultures of CAG18491/pQE15-MRS/pREP4 exhibit
an approximately 50-fold increase in MetRS activity with respect to
that of the conventional bacterial host CAG18491/pQE15/pREP4.
These values are di¡erent from those reported previously for the bac-
terial hosts B834(DE3)/pQE15/pREP4 and B834(DE3)/pQE15-MRS/
pREP4 [4], due to slight di¡erences in the assay conditions used in
determining the MetRS activity of the cell lysates.
The activity of the cell lysates was determined by adding 30 Wl of
cell lysate directly to solutions of the ATP^PPi exchange reaction
bu¡er, with a saturating concentration of methionine (750 WM), as
previously described [4]. In this case, however, a control assay in
which methionine was excluded was also analyzed for each cell lysate;
the velocities obtained for the control assays were subtracted from the
velocities observed for the cell lysates supplemented with methionine.
This procedure corrected for ATP^PPi exchange supported by the
other 19 amino acid/aaRS pairs present in the cell lysate. A similar
procedure conducted for the hosts B834(DE3)/pQE15/pREP4 and
B834(DE3)/pQE15-MRS/pREP4 yielded a measured increase in
MetRS activity of approximately 30-fold in the modi¢ed bacterial
host with respect to the conventional host.
2.3. Determination of translational activity
Bu¡ers and media were prepared according to standard protocols.
M9AA medium (50 ml) supplemented with 1 mM MgSO4, 0.2 wt%
glucose, 1 mg/l thiamine chloride and the antibiotics ampicillin (200
mg/l) and kanamycin (35 mg/l) was inoculated with 2 ml of an over-
night culture of CAG18491/pREP4/pQE15. When the turbidity of the
culture reached an optical density at 600 nm (OD600) of 0.8, a medium
shift was performed to remove methionine from the cell culture. The
cells were sedimented, the supernatant was removed, and the cell
pellet was washed twice with 20 ml of 1UM9 salts. Cells were resus-
pended in 50 ml of the M9AA medium described above, without
methionine. Test tubes containing 5-ml aliquots of the resulting cul-
ture were prepared, and were supplemented with 60 mg/l or 500 mg/l
of methionine or 2^13. A culture lacking methionine (or any ana-
logue) served as the negative control. Protein expression was induced
by addition of isopropyl-L-D-thiogalactopyranoside (Calbiochem) to a
¢nal concentration of 0.4 mM, and cultures were grown for 4.5 h.
Protein expression was monitored by SDS^PAGE of samples with
normalized OD600 and visualized by Coomassie blue staining. The
accumulation of the target protein mDHFR was taken as evidence
for incorporation of the non-natural amino acid. Incorporation was
con¢rmed by analyzing puri¢ed protein via amino acid analysis or
N-terminal sequencing.
2.4. Large scale protein expression
Larger scale production of mDHFR was conducted in 1-l or 50-ml
cultures of CAG18491/pQE15-MRS/pREP4, as described above.
After the medium shift, however, the cultures were resuspended in
either 1 l of M9AA medium lacking methionine and containing 500
mg/l of 11, or in 50 ml of M9AA medium lacking methionine and
supplemented with 500 mg/l of 4, 7, 8, or 12. Protein expression was
induced as described above. These larger scale cultures were sedi-
mented after 4.5 h, and the cell pellet was stored at 380‡C overnight.
2.5. Protein puri¢cation
mDHFR was puri¢ed from the cell pellet via immobilized metal
a⁄nity chromatography with stepwise pH gradient elution under de-
naturing conditions (Qiagen). Eluted protein was dialyzed batchwise
against distilled water for 5 days. The dialysate was lyophilized to
yield 35^40 mg of modi¢ed mDHFR from cultures grown on medium
supplemented with 500 mg/l of 11, similar to the yield obtained for
mDHFR from cultures supplemented with methionine. Similar puri-
¢cation procedures were used for the cell pellets of the 50-ml cultures
supplemented with 500 mg/l of 4, 7, 8, or 12. Protein yields obtained
from these cultures ranged from 50 to 250 Wg/50 ml.
2.6. Activation of methionine analogues in vitro
The fully active, truncated form of the wild-type MetRS was puri-
¢ed from 24-h cultures of JM101 cells carrying the plasmid pGG3
[17]. (The pGG3 plasmid was kindly donated by Professor Hieronim
Jakubowski of UMDNJ-New Jersey Medical School, Newark, NJ,
USA.) The plasmid pGG3 encodes MetRS under control of the
E. coli promoter metGp1. The enzyme was puri¢ed by size exclusion
chromatography as previously described [18].
Activation of methionine analogues by wild-type MetRS was as-
sayed via the amino acid-dependent ATP^PPi exchange reaction, also
as previously described [15,18,19]. The assay, which measures the
32P-radiolabeled ATP formed by the enzyme-catalyzed exchange of
32P-pyrophosphate (PPi) into ATP, was conducted in 150 Wl of reac-
tion bu¡er (pH 7.6, 20 mM imidazole, 0.1 mM EDTA, 10 mM L-mer-
captoethanol, 7 mM MgCl2, 2 mM ATP, 0.1 mg/ml bovine serum
albumin, and 2 mM PPi (in the form of sodium pyrophosphate
(NEN Life Science Products, Inc.) with a speci¢c activity of 0.2^0.5
TBq/mol)). Assays to determine if the methionine analogues 2^13
support PPi exchange catalyzed by MetRS were conducted in solu-
tions 75 nM in enzyme and 5 mM in the L-isomer of the analogue
with a reaction time of 20 min.
Kinetic parameters for homoallylglycine (2), homopropargylglycine
(3), trans-crotylglycine (5), and norleucine (9) have previously been
reported [15]. Quantitative kinetic parameters for 11 were obtained
with an enzyme concentration of 75 nM and analogue concentrations
of 100 WM to 20 mM. For analogue 8, an enzyme concentration of 60
nM and analogue concentrations of 2.5^35 mM were used in the
ATP^PPi exchange assay. Analogues 4 and 12 are such poor sub-
strates that only kcat/Km values could be determined accurately. For
12, enzyme concentrations of 100^150 nM and analogue concentra-
tions of 5^50 mM were used. The lower solubility of 4 precluded the
use of these high analogue concentrations, so the kcat/Km value was
estimated by calculating the slope of the plot of velocity vs. substrate
concentration at low substrate concentration [20,21]. Enzyme concen-
trations of 150 nM and analogue concentrations of 0.6^6.6 mM were
used. Measurable velocities could not be obtained for analogue 7,
owing to the very low solubility of this analogue at the pH of the
enzyme assay reaction bu¡er. Parameters were not determined for
6,6,6-tri£uoro-2-aminohexanoic acid (6), O-allylserine (10), or prop-
argylglycine (13), as these analogues did not support measurable PPi
exchange under any assay conditions. Parameters for methionine were
obtained by using concentrations ranging from 10 WM to 1 mM.
Kinetic constants were calculated by non-linear regression ¢t of the
data to a Michaelis^Menten model.
3. Results
3.1. Activation and translational activity of methionine
analogues
Previous investigations of the translational activity of me-
thionine analogues 2^9 indicated that 2, 3, and 9 support
Table 1
Kinetic parameters for methionine analogues in the ATP^PPi exchange reaction
Analogue Km (WM) kcat (s31) kcat/Km (s31 WM31) kcat/Km (Rel)a
1 24.3 þ 2 13.3 þ 0.2 5.5U1031 1
3 2 415 þ 170 2.60 þ 0.3 1.1U1033 1/500
9 4 120 þ 900 2.15 þ 0.6 5.2U1034 1/1 050
2 4 555 þ 200 1.35 þ 0.1 3.0U1034 1/1 850
5 15 675 þ 250 1.82 þ 0.6 1.2U1034 1/4 700
11 38 650 þ 2 000 1.51 þ 0.5 3.9U1035 1/14 000
aRelative to methionine.
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protein synthesis in the conventional bacterial expression host
CAG18491/pQE15/pREP4 [14]. Accordingly, 2, 3, and 9 sup-
port the highest rates of in vitro PPi exchange. Analogue 5
supports measurable, but lower levels of exchange, and over-
expression of MetRS is required to rescue its translational
activity [4]. In order to assess the ability of analogues 10^13
to serve as methionine surrogates in vivo, activation of the
analogues by MetRS in vitro was monitored via the ATP^PPi
exchange assay. Results for these studies are shown in Fig. 1,
with results for analogues 2^9 given for comparison. Of the
analogues 10^13, only 11 is indicated to support PPi exchange
under the assays conditions, at a level even lower than that
observed for 5.
The kinetic parameters for 11 were therefore determined,
yielding the values shown in Table 1. Previously determined
values for methionine and analogues 2, 3, 5, and 9 [15] are
shown for comparison. Our measured value of Km for me-
thionine matched previously reported values [22], although the
value determined for kcat was slightly lower than that re-
ported. Comparison of the kcat/Km value for 11 (3.9U1035
s31 WM31) with values for methionine and the other ana-
logues demonstrates that 11 is indeed a much poorer substrate
for MetRS, with a catalytic e⁄ciency in activation 14 000-fold
poorer than that for methionine. As the translational activity
of 5, which has a catalytic e⁄ciency 4700-fold lower than that
for methionine, could be rescued by overexpression of MetRS
in a bacterial host, it seemed likely that a similar result should
be observed for 11.
In order to test this hypothesis, bacterial hosts suitable for
testing the translational activity of methionine analogues 2^8
and 10^13 were prepared by transformation of E. coli strain
CAG18491, a methionine auxotroph, with the repressor plas-
mid pREP4 and with either of the two expression plasmids
pQE15 or pQE15-MRS (Section 2). The translational activity
of each analogue was assessed on the basis of its capacity to
support synthesis of mDHFR in methionine-depleted cultures
of CAG18491/pQE15/pREP4 or CAG18491/pQE15-MRS/
pREP4; the results are shown in Fig. 2.
The target protein was not observed in the negative control
culture of CAG18491/pQE15/pREP4, or in cultures of
CAG18491/pQE15/pREP4 or CAG18491/pQE15-MRS/
pREP4 supplemented with 4, 6, 7, 8, 10, 12, or 13. In contrast,
mDHFR was detected in both bacterial host cultures supple-
mented with methionine (1), 2, 3, or 9, as indicated by the
appearance of a protein band at the position expected for
mDHFR in SDS^PAGE, and consistent with our previous
investigations. For the negative control cultures and for cul-
tures supplemented with 5 and 11, however, the behavior of
the bacterial hosts di¡ered, as shown in Fig. 2. The target
protein mDHFR was not detected in the CAG18491/pQE15/
pREP4 cultures supplemented with 5 or 11 (Fig. 2A), while
strong induction of mDHFR was observed for CAG18491/
pQE15-MRS/pREP4 under the same conditions (Fig. 2B).
Even the unsupplemented control culture of CAG18491/
pQE15-MRS/pREP4 shows evidence of mDHFR synthesis,
suggesting that introduction of pQE15-MRS does indeed in-
crease the rate of activation of methionine in the modi¢ed
host. While we have previously reported the translational ac-
tivity of 5 under these experimental conditions, these results
indicate that overexpression of MetRS can rescue the transla-
tional activity of 11 as well, despite the fact that it is a 14 000-
fold poorer substrate for MetRS than methionine.
Supplementation by 11 at a concentration of 60 mg/l was
required to observe measurable accumulation of target pro-
tein, while supplementation with 20 mg/l was su⁄cient to
observe the same results for 5. These observations are consis-
tent with the fact that 11 is a poorer substrate for MetRS than
5 (Table 1) and with the supposition that formation of the
aminoacyl-tRNA is consequently the rate-limiting step in pro-
tein synthesis in the E. coli host. Furthermore, raising the
concentration of 11 in the culture medium to 500 mg/l (3.9
mM) improves protein yields (data not shown), suggesting
that the rate of activation of 11 is increased upon raising its
concentration in the medium, presumably by raising the intra-
Fig. 1. Activation of methionine and methionine analogues by
MetRS. The amount of PPi exchanged in 20 min, as measured in
the ATP^PPi exchange assay, is shown for 5 mM solutions of me-
thionine (1) and analogues 2^13. The background (14) is given for a
reaction mixture lacking enzyme and amino acid.
Fig. 2. SDS^PAGE analysis of mDHFR expression in bacterial cul-
tures supplemented with methionine analogues at 60 mg/l, as indi-
cated. A: The conventional bacterial host CAG18491/pQE15/
pREP4. B: The modi¢ed bacterial host CAG18491/pQE15-MRS/
pREP4.
Table 2
Extent of replacement of methionine by methionine analogues
Analogue Extent of replacement (%)
Amino acid analysis N-terminal sequencing
11 98 þ 2 94 þ 3
8 92 þ 3 87 þ 2
12 84 þ 5 84 þ 2
4 76 þ 5 79 þ 5
7 60 þ 5 56 þ 5
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cellular concentration of the analogue. We were unable to
measure the increase in intracellular concentration of the ana-
logue by amino acid analysis, as the analogue is not stable
under the analysis conditions. Still, it seemed likely that the
intracellular concentration, and therefore rate of activation, of
the other methionine analogues could be raised similarly. The
translational activity of each of the analogues 4, 6^8, 10, 12,
and 13 was therefore tested in bacterial cultures supplemented
with 500 mg/l of each compound.
3.2. Incorporation of additional methionine analogues
Expression of the target protein mDHFR was monitored by
SDS^PAGE analysis for both conventional (CAG18491/
pQE15/pREP4) and modi¢ed (CAG18491/pQE15-MRS/
pREP4) bacterial expression hosts with supplementation at
500 mg/l of 4, 6, 7, 8, 10, 12, and 13 (3.8^4.3 mM). The results
from SDS^PAGE analysis of these cultures are shown in Fig.
3. Negative control cultures did not show any target protein
synthesis, while both positive control cultures supported pro-
tein synthesis in vivo. No protein synthesis was observed in
cultures of the conventional bacterial host supplemented with
the analogues at high concentration (Fig. 3A). For the modi-
¢ed bacterial host (Fig. 3B), however, the accumulation of
target protein was observed in cultures supplemented with
500 mg/l of analogues 4, 7, 8, or 12. Increasing the concen-
tration of amino acid in the medium, coupled with overex-
pression of MetRS, is required for these methionine analogues
to support protein biosynthesis.
3.3. Protein characterization
Amino acid analysis of puri¢ed proteins produced from
cultures supplemented with 500 mg/l of 4, 7, 8, 11, and 12
was conducted to con¢rm replacement of methionine by these
analogues. Amino acid analysis shows a decrease in methio-
nine content from the expected value of 3.8 mol% in proteins
produced from cultures supplemented with the analogues. It is
impossible to detect the analogues directly by amino acid
analysis, owing to their instability under the analysis condi-
tions. If, however, depletion of methionine is assumed to re-
sult from replacement by the analogue, the observed analyses
indicate overall extents of incorporation for the analogues
ranging from 60% to 98%, as shown in Table 2. Each of the
amino acids is within experimental error ( þ 10%) of the the-
oretical values for mDHFR, with the exception of the decre-
ment in methionine content. This suggests that none of the
other 19 amino acids competes e¡ectively with the analogues
in replacing methionine.
Retention of the N-terminal (initiator) methionine in
mDHFR is expected on the basis of the identity of the penul-
timate amino acid [23], so N-terminal sequencing provided an
additional means of assessing the extent of replacement of
methionine by the analogues. Because the analogues are not
degraded under the analysis conditions, they can be detected
directly, and this analysis provides direct evidence for the
presence of the analogues in the target protein. Results for
mDHFR produced from cultures supplemented with 500 mg/l
of 11 (mDHFR-11) are shown in Fig. 4. The signal corre-
sponding to methionine elutes at 13.0 min, while that for 11
elutes at 11.7 min. The large peaks that elute at approximately
14.7 min correspond to piperidylphenylthiourea, a product of
the analysis resulting from the bu¡er, and the small peak at
Fig. 3. SDS^PAGE analysis of mDHFR synthesis in bacterial cul-
tures supplemented with methionine analogues at 500 mg/l. Cultures
were supplemented with methionine, 4, 6, 7, 8, 10, 12, and 13, as in-
dicated. A: The conventional host CAG18491/pQE15/pREP4.
B: The modi¢ed host CAG18491/pQE15-MRS/pREP4.
Fig. 4. N-terminal sequencing results indicating occupancy of the in-
itiator site in DHFR produced in bacterial cultures supplemented
with 11. N-terminal residues are shown for A: DHFR-Met, B: the
free amino acid 11, and C: DHFR-11, as determined by Edman
degradation.
Table 3
Kinetic parameters for activation of methionine analogues 4, 8, and 12 by MetRS
Analogue Km (WM) kcat (s31) kcat/Km (s31 WM31) kcat/Km (Rel)a
8 14 380 þ 900 0.17 þ 0.05 1.2U1035 1/45 600
4 NDb ND 4.3U1036 1/127 000
12 ND ND 1.6U1036 1/340 000
aRelative to methionine.
bNot determined.
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approximately 18.5 min corresponds to diethylphthalate, an
internal standard. Comparison of chromatograms of the N-
terminal residues of mDHFR and mDHFR-11 demonstrates
that the methionine that normally occupies the initiator posi-
tion of mDHFR (Fig. 4A) is replaced with 11 (Fig. 4B) in
mDFHR-11 (Fig. 4C). Similar results were observed for the
analogues 4, 7, 8, and 12. These results clearly indicate the
incorporation of a variety of methionine analogues at the
initiator site of mDHFR. Integration of the peak areas cor-
responding to methionine and to the analogues indicates up to
94% replacement of methionine; results are given for each
analogue in Table 2.
3.4. Activation of methionine analogues by MetRS in vitro
Activation of methionine analogues 4, 7, 8, and 12 by
MetRS was assayed by the ATP^PPi exchange assay as pre-
viously described. Previous characterization of the exchange
supported by 4, 7, 8, or 12 (Fig. 1) indicated that none of
them supported measurable PPi exchange at 20 min at an
analogue concentration of 5 mM. In these experiments, ana-
logues at concentrations of 15 mM were incubated with the
enzyme for 3.5 h prior to quenching. The activation of 7 could
not be measured under these conditions owing to its insolu-
bility at high concentrations. Analogues 4, 8, and 12 support
PPi exchange at levels greater than background under these
experimental conditions, while analogues 6, 10 and 13 do not
(data not shown). The kinetic parameters for 4, 8, and 12 were
therefore measured as previously described. As shown in Ta-
ble 3, the analogues are increasingly poor substrates for the
enzyme, with kcat/Km values up to 340 000-fold lower than
those observed for methionine.
4. Discussion
Combined with our previous results detailing the incorpo-
ration of 2, 3, and 5, the incorporation of 4, 7, 8, 11, and 12
into proteins in vivo demonstrates the promiscuity of the
translational apparatus toward methionine analogues under
appropriate experimental conditions. Increasing the MetRS
activity of the cellular host and/or increasing the concentra-
tion of analogue in the medium increases the rate of activation
of analogues 4, 7, 8, 11, and 12 su⁄ciently to rescue their
translational activity in vivo. These procedures permit the in-
corporation of methionine analogues that are up to 340 000-
fold poorer substrates for MetRS in activation than methio-
nine, demonstrating that much poorer substrates than previ-
ously imagined can be utilized by the protein biosynthesis
machinery under appropriate experimental conditions.
Understanding the features of the analogue that are impor-
tant for activation and incorporation may facilitate not only
the rational design of additional novel methionine analogues,
but also the design of mutant forms of MetRS. In these and
previous studies, the importance of side chain length in facil-
itating activation of an analogue by MetRS is illustrated, as 7,
8, 10, 12, and 13 are activated much less e⁄ciently by MetRS
than 2, 3, 5, 9, and 11 (Table 1). Although 4 has the same side
chain length as methionine, the conformational restriction
placed on the side chain by the cis-conformation of the double
bond imposes on 4 a geometry very di¡erent from that of
methionine bound at the active site of MetRS [24]. The im-
portance of p- or Z-electron density in the amino acid side
chain is suggested by the fact that the methionine thioether
makes two hydrogen bonds ^ one with the side chain of
Tyr260 and another with the backbone NH of Leu13 ^ in
the active site of MetRS [24]. Therefore, although the geo-
metries or side chain lengths of 4, 11, and 12 are di¡erent
from those of methionine, the availability of Z-electrons
near the N-position of these analogues is likely to play a role
in their activation by MetRS. The presence of Z-electrons near
the N-positions of 3 and 11 is almost certainly critical for
activation, given the side chain geometries of these analogues
[14], and we have recently found that the availability of elec-
tron density at the N-position is essential in the activation of
azido amino acids [25].
The observed promiscuity of MetRS may result not only
from structural and electronic similarities of the methionine
analogues examined here, but also from certain unique fea-
tures of the enzyme. Comparison of the crystal structures of
the free [26] and methionine-bound [24] forms of MetRS
shows that the active site undergoes signi¢cant conformation-
al changes upon methionine binding; this £exibility may be
important in enabling MetRS to activate methionine ana-
logues with varying side chain lengths and chemical function-
ality. Furthermore, MetRS does not exhibit general editing
mechanisms common to other aaRS, which may permit
MetRS to charge tRNAMet with a broad range of non-natural
amino acids. Indeed, mutation of residues in the editing site of
valyl-tRNA synthetase permits incorporation of aminobuty-
rate in place of valine in vivo [27], and similar strategies to
eliminate editing activity in other aaRS appear likely to prove
useful in expanding the synthetic versatility of the translation-
al apparatus.
The conformational £exibility of the active site and the lack
of general editing by MetRS suggest that this enzyme might
be particularly suited for directed evolution strategies aimed
at incorporating novel methionine analogues into proteins in
vivo. Because even extremely poor substrates for MetRS can
support protein synthesis under appropriate conditions, even
modest gains in the rates of activation of analogues by MetRS
may be su⁄cient to permit incorporation of new methionine
analogues by the methods described here. Similar strategies
will likely be generally applicable to all aaRS. Methods to
expand the set of translationally active methionine analogues
via directed evolution are currently under investigation.
The results reported here illustrate one of an increasing
number of strategies for the incorporation of non-natural
amino acids into proteins in vivo. Given the many methods
by which one can tailor the aaRS activity of a bacterial host,
the prospects appear promising for substantial broadening of
the scope of protein engineering in vivo through the incorpo-
ration of chemically novel amino acids.
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